Novartis hives treatment ligelizumab is moving to late-stage trials after it showed indications of outperforming Xolair, the existing treatment sold by both Novartis and Roche. Xolair has lost patent protection in both the U.S. and Europe. (Reuters)

Brexit is set to do more harm than good to the U.K. biopharma industry, according to a survey. Respondents said the country’s decision to exit the E.U. could result in Britain being a less attractive destination to both pharma companies and employees. (Endpoints)

Seven out of 10 patients responded to the second-highest dose of an Amgen bispecific antibody for multiple myeloma. A trial with the highest dose was discontinued because of toxicity. The Food and Drug Administration has given fast-track status to AMG420. (Reuters)

Grocery retailer Kroger is planning to launch branded sections in Walgreens Boots Alliance stores. Thirteen Kroger Express sections will open in Walgreens stores around Cincinnati next year. The move is designed to boost customer loyalty for both brands. (Wall Street Journal)

ResMed is planning to acquire Propeller Health in a $225 million deal. The acquisition is the latest part of San Diego-based ResMed’s five-year push into connected healthcare. Propeller develops sensors that track the usage of asthma and COPD patients’ inhalers. (Xconomy)